Evaluation of Protein in the Urine in Patients Receiving Bevacizumab

Completed

Conditions studied: Colon Cancer, Rectal Cancer

In brief

This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.

Key facts

Study ID

NCT00849394

Run by

North Texas Veterans Healthcare System

People needed

106

Starts

2007-11-01

Expected to finish

2012-06-01

Last updated by the study team

2012-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be 18 years older
• Patients must be receiving his/her first dose of bevacizumab
• Patients must sign an informed consent

You may not qualify if…

• Patients receiving > 10 mg/kg doses of bevacizumab

Where it is running

• VA North Texas Health Care System — Dallas, Texas, United States
• Parkland Health and Hospital System — Dallas, Texas, United States
• UT Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.